Effects of cytochalasin congeners, microtubule-directed agents, and doxorubicin alone or in combination against human ovarian carcinoma cell lines in vitro

Table 5 Chou-Talalay statistics on the mean IC₅₀ values between cytochalasin B, 21, 22-dihydrocytochalasin B, doxorubicin, and paclitaxel against SKOV3 and SKVLB1 human ovarian carcinoma

Cell line	Cytochalasin (μM)	Clinically approved agent (μM)	DRI Cyt^a	DRI CAA^b	CI
SKOV3	0.6 CB	0.0067 ADR	3.46	8.20	0.41
	0.6 CB	0.0023 Tax	3.46	6.99	0.43
	0.76 DiHCB	0.0065 ADR	5.23	10.9	0.28
	0.76 DiHCB	0.0030 Tax	5.23	12.5	0.27
SKVLB1	0.6 CB	0.30 ADR	4.07	15.7	0.30
	0.6 CB	0.40 Tax	4.07	19.7	0.29
	1.12 DiHCB	0.29 ADR	5.27	17.5	0.25
	1.12 DiHCB	0.30 Tax	5.27	22.7	0.23

Mean values for drug concentrations, dose reduction indices, and combination indices were derived from the points used in the IC₅₀ isobolograms, excluding single agent administrations
CI combination index
^aDose reduction index for the indicated cytochalasin
^bDose reduction index for the indicated currently approved agent

ISSN: 1471-2407